Search

Your search keyword '"Arcari Annalisa"' showing total 244 results
Start Over Author "Arcari Annalisa"
Sorry, I don't understand your search. ×
244 results on '"Arcari Annalisa"'

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

2. Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature

Author

Arcari Annalisa, Bassi Simona, Pochintesta Lara, Trabacchi Elena, Moroni Carlo Filippo, Rossi Angela, Zanlari Luca, and Vallisa Daniele

Subjects
Chronic lymphocytic leukemia, B-cell receptor inhibitors, Allogeneic hematopoietic stem cell transplantation, TP53 mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation.

Published
2017
Full Text
View/download PDF

3. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Author

Malinverni, Chiara, Bernardelli, Andrea, Glimelius, Ingrid, Mirandola, Massimo, Smedby, Karin E., Tisi, Maria Chiara, Giné, Eva, Albertsson-Lindblad, Alexandra, Marin-Niebla, Ana, Di Rocco, Alice, Moita, Filipa, Sciarra, Roberta, Bašić-Kinda, Sandra, Hess, Georg, Ohler, Anke, Eskelund, Christian W., Re, Alessandro, Ferrarini, Isacco, Kolstad, Arne, Räty, Riikka, Quaglia, Francesca Maria, Eyre, Toby A., Scapinello, Greta, Stefani, Piero Maria, Morello, Lucia, Nassi, Luca, Hohaus, Stefan, Ragaini, Simone, Zilioli, Vittorio Ruggero, Bruna, Riccardo, Cocito, Federica, Arcari, Annalisa, Jerkeman, Mats, and Visco, Carlo

Published
2024
Full Text
View/download PDF

4. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Author

Gini, Guido, Tani, Monica, Tucci, Alessandra, Marcheselli, Luigi, Cesaretti, Marina, Bellei, Monica, Pascarella, Anna, Ballerini, Filippo, Petrini, Mauro, Merli, Francesco, Olivieri, Attilio, Lanza, Francesco, Annibali, Ombretta, Zilioli, Vittorio Ruggero, Liberati, Anna Marina, Tisi, Maria Chiara, Arcari, Annalisa, Marino, Dario, Musuraca, Gerardo, Pavone, Vincenzo, Fabbri, Alberto, Pozzi, Samantha, Mannina, Donato, Plenteda, Caterina, Celli, Melania, and Luminari, Stefano

Published
2023
Full Text
View/download PDF

5. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

Author

Chiappella, Annalisa, Dodero, Anna, Evangelista, Andrea, Re, Alessandro, Orsucci, Lorella, Usai, Sara Veronica, Castellino, Claudia, Stefoni, Vittorio, Pinto, Antonio, Zanni, Manuela, Ciancia, Rosanna, Ghiggi, Chiara, Rossi, Francesca Gaia, Arcari, Annalisa, Ilariucci, Fiorella, Zilioli, Vittorio Ruggero, Flenghi, Leonardo, Celli, Melania, Volpetti, Stefano, Benedetti, Fabio, Ballerini, Filippo, Musuraca, Gerardo, Bruna, Riccardo, Patti, Caterina, Leonardi, Francesco, Arcaini, Luca, Magagnoli, Massimo, Cavallo, Federica, Bermema, Anisa, Tucci, Alessandra, Boccomini, Carola, Ciccone, Giovannino, Carniti, Cristiana, Pileri, Stefano Aldo, and Corradini, Paolo

Published
2023
Full Text
View/download PDF

6. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma

Author

Arcari, Annalisa, Rigacci, Lugi, Tucci, Alessandra, Puccini, Benedetta, Usai, Sara Veronica, Cavallo, Federica, Fabbri, Alberto, Balzarotti, Monica, Pelliccia, Sabrina, Luminari, Stefano, Pennese, Elsa, Zilioli, Vittorio Ruggero, Mahmoud, Abdurraouf Mokhtar, Musuraca, Gerardo, Marino, Dario, Sartori, Roberto, Botto, Barbara, Gini, Guido, Zanni, Manuela, Hohaus, Stefan, Tarantini, Giuseppe, Flenghi, Leonardo, Tani, Monica, Di Rocco, Alice, Merli, Michele, Vallisa, Daniele, Pagani, Chiara, Nassi, Luca, Dessì, Daniela, Ferrero, Simone, Cencini, Emanuele, Bernuzzi, Patrizia, Mammi, Caterina, Marcheselli, Luigi, Tabanelli, Valentina, Spina, Michele, and Merli, Francesco

Published
2023
Full Text
View/download PDF

7. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL

Author

Tisi, Maria Chiara, Moia, Riccardo, Patti, Caterina, Evangelista, Andrea, Ferrero, Simone, Spina, Michele, Tani, Monica, Botto, Barbara, Celli, Melania, Puccini, Benedetta, Cencini, Emanuele, Di Rocco, Alice, Chini, Claudio, Ghiggi, Chiara, Zambello, Renato, Zanni, Manuela, Sciarra, Roberta, Bruna, Riccardo, Ferrante, Martina, Pileri, Stefano Alessandro, Quaglia, Francesca Maria, Stelitano, Caterina, Re, Alessandro, Volpetti, Stefano, Zilioli, Vittorio Ruggero, Arcari, Annalisa, Merli, Francesco, and Visco, Carlo

Published
2023
Full Text
View/download PDF

8. IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study

Author

Cox, M. Christina, Marcheselli, Luigi, Scafetta, Giorgia, Visco, Carlo, Hohaus, Stefan, Annibali, Ombretta, Musuraca, Gerardo, Fabbri, Alberto, Cantonetti, Maria, Pelliccia, Sabrina, Papotti, Robel, Petrucci, Luigi, Tani, Monica, Battistini, Roberta, Arcari, Annalisa, Luminari, Stefano, Lopez, Gianluca, Alma, Eleonora, Pupo, Livio, Carli, Giuseppe, Marchesi, Francesco, Re, Francesca, Scarpino, Stefania, D’amore, Emanuele S. G., Larocca, Luigi M., Bianchi, Antonella, Pepe, Giuseppina, Natalino, Fiammetta, Anticoli-Borza, Paola, Cenfra, Natalia, Andriani, Alessandro, Abruzzese, Elisabetta, Tesei, Cristiano, Leoncini, Lorenzo, Asioli, Silvia, Ruco, Luigi, and Di Napoli, Arianna

Published
2022
Full Text
View/download PDF

9. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Author

Rusconi, Chiara, Cheah, Chan Y., Eyre, Toby A., Tucker, David, Klener, Pavel, Giné, Eva, Crucitti, Lara, Muzi, Cristina, Iadecola, Sara, Infante, Gabriele, Bernard, Sophie, Auer, Rebecca L., Pagani, Chiara, Duglosz-Danecka, Monika, Mocikova, Heidi, van Meerten, Tom, Cencini, Emanuele, Marin-Niebla, Ana, Williams, Michael E., Angelillo, Piera, Nicoli, Paolo, Arcari, Annalisa, Morello, Lucia, Mannina, Donato, Vitagliano, Orsola, Sartori, Roberto, Chiappella, Annalisa, Sciarra, Roberta, Stefani, Piero M., Dreyling, Martin, Seymour, John F., and Visco, Carlo

Published
2022
Full Text
View/download PDF

10. Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.

Author

Arcari, Annalisa, Morello, Lucia, Borotti, Elena, Ronda, Elena, Rossi, Angela, and Vallisa, Daniele

Abstract

Simple Summary: The therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) has dramatically changed in recent years, with a shift from chemoimmunotherapy towards many new targeted agents, such as Bruton Tyrosine Kinase inhibitors (BTKi) and anti-BCL-2. We now need an accurate re-definition of prognostic/predictive parameters to support clinicians in choosing the more appropriate option. This review explores recent advances in the molecular biology of chronic lymphocytic leukemia, with the aim of identifying the most important biomarkers to define prognosis and to guide first-line and second-line treatment. Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease's pathogenesis. Very heterogeneous prognostic subgroups have been identified by the mutational status of immunoglobulin heavy variable genes (IGVH), FISH analysis and molecular evaluation of TP53 mutations. Next-generation sequencing (NGS) technologies have provided a deeper characterization of the genomic and epigenomic landscape of CLL. New therapeutic targets have led to a progressive reduction of traditional chemoimmunotherapy in favor of specific biological agents. Furthermore, in the latest clinical trials, the minimal residual disease (MRD) has emerged as a potent marker of outcome and a guide to treatment duration. This review focuses on recent insights into the understanding of CLL biology. We also consider the translation of these findings into the development of risk-adapted and targeted therapeutic approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, and Bari, Alessia

Subjects
CLINICAL trials, FOLLICULAR lymphoma, POSITRON emission tomography, OVERALL survival, PROGRESSION-free survival
Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1–3a FL/ stage II‐IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post‐induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1–3 was considered negative (CMR), whereas DS4‐5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients—52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3–5)—were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4–5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%–70%). The 5-yr PFS rate for PET neg (DS1–3) and PET pos (DS4–5) patients was 71% (95%CI: 67%–75%) and 36% (95%CI: 25%–46%), respectively, with HR 3.49 (95%CI: 2.57–4.72). Five-year PFS was worse as DS increased, with 74% (70%–78%), 58% (48%–67%; HR 1.71; p = 0.001)] and 36% (25%–46%; HR 3.88; p < 0.001) in DS1–2, DS3 and DS4–5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%–96%), with 96% (95%CI: 94–97) and 82% (95%CI: 72%–89%) in EOI PET negative (DS1–3) and positive (DS4–5), respectively (HR 4.48; p < 0.001). When DS was associated with FLIPI-2, patients with DS3 or DS1–2 with high FLIPI-2 (3–5) experienced worse OS than patients with DS1–2 and low FLIPI-2 (1–2) (p = 0.003). Conclusion: This study shows that DS is a reliable prognostic tool to evaluate EOI PET in follicular lymphoma patients, with prognostic value maintained both in the standard and experimental arms, making metabolic imaging a robust tool to assess response in FL. Moreover, although preliminary, this study provides further information on DS3 patients, who are considered as CMR but show a less favourable PFS than DS1–2 patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

Author

Merli, Michele, Luminari, Stefano, Farina, Lucia, Cocito, Federica, Defrancesco, Irene, Gini, Guido, Arcari, Annalisa, Scapinello, Greta, Gentile, Massimo, Goldaniga, Maria, Loseto, Giacomo, Cencini, Emanuele, Greco, Antonino, Molinari, Anna Lia, Ferrario, Andrea, Bianchi, Benedetta, Mora, Barbara, Bertù, Lorenza, Saturni, Vincenzo, Bergamini, Fabio, Fabbri, Nicole, Rossi, Francesca Gaia, Bolis, Silvia, Passamonti, Francesco, and Arcaini, Luca

Published
2020
Full Text
View/download PDF

15. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial

Author

Ferreri, Andrés J M, Sassone, Marianna, Zaja, Francesco, Re, Alessandro, Spina, Michele, Rocco, Alice Di, Fabbri, Alberto, Stelitano, Caterina, Frezzato, Maurizio, Rusconi, Chiara, Zambello, Renato, Couto, Suzana, Ren, Yan, Arcari, Annalisa, Bertoldero, Giovanni, Nonis, Alessandro, Scarfò, Lydia, Calimeri, Teresa, Cecchetti, Caterina, Chiozzotto, Marianna, Govi, Silvia, and Ponzoni, Maurilio

Published
2017
Full Text
View/download PDF

16. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

17. Biological features and outcome of diffuse large B‐cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective ‘Elderly Project’ by the Fondazione Italiana Linfomi

Author

Arcari, Annalisa, primary, Tabanelli, Valentina, additional, Merli, Francesco, additional, Marcheselli, Luigi, additional, Merli, Michele, additional, Balzarotti, Monica, additional, Zilioli, Vittorio Ruggero, additional, Fabbri, Alberto, additional, Cavallo, Federica, additional, Casaluci, Gloria Margiotta, additional, Tucci, Alessandra, additional, Puccini, Benedetta, additional, Pennese, Elsa, additional, Di Rocco, Alice, additional, Zanni, Manuela, additional, Flenghi, Leonardo, additional, Gini, Guido, additional, Sartori, Roberto, additional, Chiappella, Annalisa, additional, Usai, Sara Veronica, additional, Tani, Monica, additional, Marino, Dario, additional, Arcaini, Luca, additional, Vallisa, Daniele, additional, and Spina, Michele, additional

Published
2023
Full Text
View/download PDF

18. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

19. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)

Author

Tucci, Alessandra, primary, Merli, Francesco, additional, Fabbri, Alberto, additional, Marcheselli, Luigi, additional, Pagani, Chiara, additional, Puccini, Benedetta, additional, Marino, Dario, additional, Zanni, Manuela, additional, Pennese, Elsa, additional, Flenghi, Leonardo, additional, Arcari, Annalisa, additional, Botto, Barbara, additional, Celli, Melania, additional, Mammi, Caterina, additional, Re, Alessandro, additional, Campostrini, Giulia, additional, Tafuri, Agostino, additional, Zilioli, Vittorio R., additional, Cencini, Emanuele, additional, Sartori, Roberto, additional, Bottelli, Chiara, additional, Merli, Michele, additional, Petrucci, Luigi, additional, Gini, Guido, additional, Balzarotti, Monica, additional, Cavallo, Federica, additional, Musuraca, Gerardo, additional, Luminari, Stefano, additional, Rossi, Giuseppe, additional, and Spina, Michele, additional

Published
2022
Full Text
View/download PDF

20. PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Author

Balzarotti, Monica, primary, Ricardi, Umberto, additional, Spina, Michele, additional, Evangelista, Andrea, additional, Tucci, Alessandra, additional, Cavallo, Federica, additional, Zanni, Manuela, additional, Arcari, Annalisa, additional, Zilioli, Vittorio Ruggero, additional, Sartori, Roberto, additional, Merli, Francesco, additional, Re, Francesca, additional, Vitolo, Umberto, additional, Deidda, Maria Assunta, additional, Melis, Luca, additional, Dessì, Daniela, additional, Rodari, Marcello, additional, Santoro, Armando, additional, Gaidano, Gianluca, additional, Ciccone, Giovannino, additional, Chauvie, Stephane, additional, and Cabras, Maria Giuseppina, additional

Published
2022
Full Text
View/download PDF

21. Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Author

Calimeri, Teresa, primary, Erbella, Federico, additional, Orsucci, Lorella, additional, Aloisi, Teresa, additional, Arcari, Annalisa, additional, Botta, Cirino, additional, Cuccaro, Annarosa, additional, Frascione, Pio Manlio Mirko, additional, Girlanda, Stefania, additional, Gotti, Manuel, additional, Mariani, Sabrina, additional, Nassi, Luca, additional, Ronconi, Fioravante, additional, Schiattone, Luana, additional, Tucci, Alessandra, additional, Verga, Luisa, additional, Mercurio, Vincenzo, additional, Fiore, Paolo, additional, Steffanoni, Sara, additional, Ciceri, Fabio, additional, and Ferreri, Andrés J.M., additional

Published
2022
Full Text
View/download PDF

22. The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Author

Chiappella, Annalisa, primary, Dodero, Anna, additional, Evangelista, Andrea, additional, Re, Alessandro, additional, Orsucci, Lorella, additional, Usai, Sara Veronica, additional, Castellino, Claudia, additional, Stefoni, Vittorio, additional, Pinto, Antonio, additional, Zanni, Manuela, additional, Ciancia, Rosanna, additional, Ghiggi, Chiara, additional, Rossi, Francesca Gaia, additional, Arcari, Annalisa, additional, Ilariucci, Fiorella, additional, Zilioli, Vittorio Ruggero, additional, Flenghi, Leonardo, additional, Celli, Melania, additional, Volpetti, Stefano, additional, Benedetti, Fabio, additional, Ballerini, Filippo, additional, Musuraca, Gerardo, additional, Bruna, Riccardo, additional, Patti, Caterina, additional, Leonardi, Francesco, additional, Arcaini, Luca, additional, Magagnoli, Massimo, additional, Cavallo, Federica, additional, Tabanelli, Valentina, additional, Ciccone, Giovannino, additional, Pileri, Stefano A, additional, and Corradini, Paolo, additional

Published
2022
Full Text
View/download PDF

23. The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi

Author

Cencini, Emanuele, primary, Tucci, Alessandra, additional, Puccini, Benedetta, additional, Cavallo, Federica, additional, Luminari, Stefano, additional, Usai, Sara Veronica, additional, Fabbri, Alberto, additional, Pennese, Elsa, additional, Marino, Dario, additional, Zilioli, Vittorio Ruggero, additional, Balzarotti, Monica, additional, Petrucci, Luigi, additional, Tafuri, Agostino, additional, Arcari, Annalisa, additional, Botto, Barbara, additional, Zanni, Manuela, additional, Hohaus, Stefan, additional, Sartori, Roberto, additional, Merli, Michele, additional, Gini, Guido, additional, Al Essa, Wael, additional, Musurca, Gerardo, additional, Tani, Monica, additional, Nassi, Luca, additional, Daffini, Rosa, additional, Mammi, Caterina, additional, Marcheselli, Luigi, additional, Bocchia, Monica, additional, Spina, Michele, additional, and Merli, Francesco, additional

Published
2022
Full Text
View/download PDF

24. Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

Author

De Matteis, Serena, primary, Casadei, Beatrice, additional, Lolli, Ginevra, additional, Dicataldo, Michele, additional, Barbato, Francesco, additional, Dan, Elisa, additional, Paccagnella, Andrea, additional, Sinigaglia, Barbara, additional, Bertuzzi, Clara, additional, Arcari, Annalisa, additional, Zazzeroni, Luca, additional, Bernuzzi, Patrizia, additional, Laprovitera, Noemi, additional, Storci, Gianluca, additional, Bertuccio, Salvatore Nicola, additional, Ferracin, Manuela, additional, Bonafè, Massimiliano, additional, Zinzani, Pier Luigi, additional, and Bonifazi, Francesca, additional

Published
2022
Full Text
View/download PDF

25. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

26. DLBCL with an associated IgM serum paraprotein (IgMs- DLBCL) has poor prognosis and frequent mutations in MYD88, CD79B and TP53 genes

Author

Cox, Maria Christina, primary, Marcheselli, Luigi, additional, Scafetta, Giorgia, additional, Visco, Carlo, additional, Hohaus, Stefan, additional, Annibali, Ombretta, additional, Musuraca, Gerardo, additional, Fabbri, Alberto, additional, Cantonetti, Maria, additional, Pelliccia, Sabrina, additional, Papotti, Robel, additional, Petrucci, Luigi, additional, Tani, Monica, additional, Battistini, Roberta, additional, Arcari, Annalisa, additional, Luminari, Stefano, additional, Lopez, Gianluca, additional, Alma, Eleonora, additional, Pupo, Livio, additional, Carli, Giuseppe, additional, Marchesi, Francesco, additional, Re, Francesca, additional, Scarpino, Stefania, additional, D’amore, Emanuele, additional, Larocca, Luigi M, additional, Bianchi, Antonella, additional, Pepe, Giuseppina, additional, Natalino, Fiammetta, additional, Anticoli-Borza, Paola, additional, Cenfra, Natalia, additional, Andriani, Alessandro, additional, Abruzzese, Elisabetta, additional, Tesei, Cristiano, additional, Leoncini, Lorenzo, additional, Asioli, Silvia, additional, Ruco, Luigi, additional, and Napoli, Arianna Di, additional

Published
2022
Full Text
View/download PDF

27. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

Author

Casadei, Beatrice, primary, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Patti, Caterina, additional, Stefani, Piero Maria, additional, Cuneo, Antonio, additional, Margiotta Casaluci, Gloria, additional, Visco, Carlo, additional, Gini, Guido, additional, Pane, Fabrizio, additional, D’Alò, Francesco, additional, Luzi, Debora, additional, Cantonetti, Maria, additional, Pozzi, Samantha, additional, Musuraca, Gerardo, additional, Rosignoli, Chiara, additional, Arcari, Annalisa, additional, Kovalchuk, Sofya, additional, Tani, Monica, additional, Tisi, Maria Chiara, additional, Petrini, Mario, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

28. The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.

Author

Cencini, Emanuele, Tucci, Alessandra, Puccini, Benedetta, Cavallo, Federica, Luminari, Stefano, Usai, Sara Veronica, Fabbri, Alberto, Pennese, Elsa, Marino, Dario, Zilioli, Vittorio Ruggero, Balzarotti, Monica, Petrucci, Luigi, Tafuri, Agostino, Arcari, Annalisa, Botto, Barbara, Zanni, Manuela, Hohaus, Stefan, Sartori, Roberto, Merli, Michele, and Gini, Guido

Subjects
OLDER patients, DIFFUSE large B-cell lymphomas, OLDER people, MORTALITY, GERIATRIC assessment
Abstract

The Elderly Prognostic Index (EPI) is based on the integration of a simplified geriatric assessment, hemoglobin levels and International Prognostic Index and has been validated to predict overall survival in older patients with diffuse large B‐cell lymphoma (DLBCL). In this study, we evaluated the ability of EPI to predict the risk of early mortality. This study included all patients registered in the Elderly Project for whom treatment details and a minimum follow‐up of 3 months were available. Three main treatment groups were identified based on the anthracycline amount administered: cases receiving >70% of the theoretical anthracyclines dose (Full Dose [FD] group), ≤70% (Reduced Dose [RD]) and palliative therapy (PT; no anthracyclines). The primary endpoint was early mortality rate, defined as death for any cause occurring within 90 days from diagnosis. We identified 1150 patients with a median age of 76 years (range 65–94). Overall, 69 early deaths were observed, accounting for 19% of all reported deaths. The cumulative rate of early mortality at 90 days was 6.0%. Comparing early with delayed deaths, we observed a lower frequency of deaths due to lymphoma progression (42% vs. 75%; p < 0.001) and a higher frequency due to toxicity and infections (22% vs. 4%, p < 0.001, and 22% vs. 3%, p < 0.001, respectively) for early events. A multivariable logistic analysis on 931 patients (excluding PT) confirmed an independent association of high‐risk EPI (odds ratio [OR] 3.60; 95% confidence interval [CI] 1.15–11.2) and bulky disease (OR 2.08; 95% CI 1.09–3.97) with the risk of early mortality. The cumulative incidence of early mortality for older patients with DLBCL is not negligible and is mainly associated with non‐lymphoma related events. For patients receiving anthracyclines, high‐risk EPI and bulky disease are associated with a higher probability of early mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Author

Gini, Guido, primary, Tani, Monica, additional, Bassan, Renato, additional, Tucci, Alessandra, additional, Ballerini, Filippo, additional, Sampaolo, Michela, additional, Merli, Francesco, additional, Re, Francesca, additional, Olivieri, Attilio, additional, Petrini, Mauro, additional, Annibali, Ombretta, additional, Liberati, Anna Marina, additional, Visco, Carlo, additional, Arcari, Annalisa, additional, Storti, Sergio, additional, Fabbri, Alberto, additional, Musuraca, Gerardo, additional, Zilioli, Vittorio Ruggero, additional, Cox, M. Christina, additional, and Luminari, Stefano, additional

Published
2021
Full Text
View/download PDF

30. Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Author

Tisi, Maria Chiara, primary, Nassi, Luca, additional, Patti, Caterina, additional, Spina, Michele, additional, Ferrero, Simone, additional, Tani, Monica, additional, Botto, Barbara, additional, Molinari, Anna Lia, additional, Puccini, Benedetta, additional, Cencini, Emanuele, additional, Di Rocco, Alice, additional, Chini, Claudio, additional, Ghiggi, Chiara, additional, Zambello, Renato, additional, Zanni, Manuela, additional, Sciarra, Roberta, additional, Ferrante, Martina, additional, Stelitano, Caterina, additional, Re, Alessandro, additional, Volpetti, Stefano, additional, Zilioli, Vittorio Ruggero, additional, Arcari, Annalisa, additional, Merli, Francesco, additional, and Visco, Carlo, additional

Published
2021
Full Text
View/download PDF

31. Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Author

Merli, Francesco, primary, Spina, Michele, additional, Tucci, Alessandra, additional, Rigacci, Luigi, additional, Cavallo, Federica, additional, Cabras, Maria Giuseppina, additional, Alvarez, Isabel, additional, Fabbri, Alberto, additional, Re, Alessandro, additional, Puccini, Benedetta, additional, Ferrero, Simone, additional, Usai, Sara Veronica, additional, Ferrari, Angela, additional, Cencini, Emanuele, additional, Pennese, Elsa, additional, Zilioli, Vittorio Ruggero, additional, Marino, Dario, additional, Balzarotti, Monica, additional, Cox, M. Christina, additional, Zanni, Manuela, additional, Di Rocco, Alice, additional, Lleshi, Arben, additional, Botto, Barbara, additional, Hohaus, Stefan, additional, Merli, Michele, additional, Sartori, Roberto, additional, Gini, Guido, additional, Nassi, Luca, additional, Musuraca, Gerardo, additional, Tani, Monica, additional, Bottelli, Chiara, additional, Kovalchuk, Sofia, additional, Re, Francesca, additional, Flenghi, Leonardo, additional, Molinari, Anna Lia, additional, Tarantini, Giuseppe, additional, Chimienti, Emanuela, additional, Marcheselli, Luigi, additional, Mammi, Caterina, additional, Luminari, Stefano, additional, and Arcari, Annalisa, additional

Published
2021
Full Text
View/download PDF

32. Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Author

Visco, Carlo, primary, Tabanelli, Valentina, additional, Peracchio, Claudia, additional, Evangelista, Andrea, additional, Tisi, Maria Chiara, additional, Merli, Anna, additional, Fraenza, Costanza, additional, Fiori, Stefano, additional, Re, Alessandro, additional, Castellino, Claudia, additional, Zilioli, Vittorio Ruggero, additional, Piazza, Francesco, additional, Corradini, Paolo, additional, Hohaus, Stefan, additional, Musuraca, Gerardo, additional, Ferla, Valeria, additional, Puccini, Benedetta, additional, Cavallo, Federica, additional, Ballerini, Filippo, additional, Sciarra, Roberta, additional, Di Rocco, Alice, additional, Arcari, Annalisa, additional, Boccomini, Carola, additional, Merli, Francesco, additional, Gini, Guido, additional, Tani, Monica, additional, Bruna, Riccardo, additional, Pavone, Vincenzo, additional, Ferreri, Andrés J M, additional, Santoro, Armando, additional, Patti, Caterina, additional, Loseto, Giacomo, additional, Ladetto, Marco, additional, Merli, Michele, additional, Spina, Michele, additional, Zinzani, Pier Luigi, additional, Stefani, Pietro Maria, additional, Usai, Sara Veronica, additional, Stelitano, Caterina, additional, Volpetti, Stefano, additional, Pileri, Stefano A, additional, and Balzarotti, Monica, additional

Published
2021
Full Text
View/download PDF

33. CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

Author

Gini, Guido, primary, Di Rocco, Alice, additional, Nassi, Luca, additional, Arcari, Annalisa, additional, Tisi, Maria Chiara, additional, Loseto, Giacomo, additional, Olivieri, Attilio, additional, Gentile, Massimo, additional, Annibali, Ombretta, additional, Cabras, Maria Giuseppina, additional, Chiappella, Annalisa, additional, Rusconi, Chiara, additional, Ferreri, Andrés José María, additional, and Balzarotti, Monica, additional

Published
2021
Full Text
View/download PDF

34. Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Author

Chiappella, Annalisa, primary, Carniti, Cristiana, additional, Re, Alessandro, additional, Castellino, Claudia, additional, Evangelista, Andrea, additional, Tabanelli, Valentina, additional, Ciancia, Rosanna, additional, Orsucci, Lorella, additional, Pinto, Antonello, additional, Usai, Sara Veronica, additional, Arcari, Annalisa, additional, Ilariucci, Fiorella, additional, Rossi, Francesca Gaia, additional, Benedetti, Fabio, additional, Flenghi, Leonardo, additional, Ghiggi, Chiara, additional, Molinari, Anna Lia, additional, Stefoni, Vittorio, additional, Volpetti, Stefano, additional, Zilioli, Vittorio Ruggero, additional, Ballerini, Filippo, additional, Bruna, Riccardo, additional, Cavallo, Federica, additional, Musuraca, Gerardo, additional, Patti, Caterina, additional, Re, Francesca, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Zanni, Manuela, additional, Dodero, Anna, additional, Pileri, Stefano A, additional, Ciccone, Giovannino, additional, and Corradini, Paolo, additional

Published
2021
Full Text
View/download PDF

35. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Author

Luminari, Stefano, primary, Nizzoli, Maria Elena, additional, Chiarenza, Annalisa, additional, Mannina, Donato, additional, Tucci, Alessandra, additional, Boccomini, Carola, additional, Farina, Lucia, additional, Olivieri, Jacopo, additional, Marcheselli, Luigi, additional, Ferrero, Simone, additional, Arcaini, Luca, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Califano, Catello, additional, Merli, Michele, additional, Bari, Alessia, additional, Conconi, Annarita, additional, Re, Francesca, additional, Balzarotti, Monica, additional, Ladetto, Marco, additional, Patti, Caterina, additional, Pinto, Antonello, additional, Cabras, Maria Giuseppina, additional, Musto, Pellegrino, additional, Gini, Guido, additional, Arcari, Annalisa, additional, Manni, Martina, additional, Versari, Annibale, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

36. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience

Author

Massaro, Fulvio, primary, Pavone, Vincenzo, additional, Stefani, Piero Maria, additional, Botto, Barbara, additional, Pulsoni, Alessandro, additional, Patti, Caterina, additional, Cantonetti, Maria, additional, Visentin, Andrea, additional, Scalzulli, Potito Rosario, additional, Rossi, Andrea, additional, Galimberti, Sara, additional, Cimminiello, Michele, additional, Gini, Guido, additional, Musso, Maurizio, additional, Sorio, Marco, additional, Arcari, Annalisa, additional, Zilioli, Vittorio Ruggero, additional, Luppi, Mario, additional, Mannina, Donato, additional, Fabbri, Alberto, additional, Pietrantuono, Giuseppe, additional, Annibali, Ombretta, additional, Tafuri, Agostino, additional, Prete, Eleonora, additional, Mulè, Antonino, additional, Barbolini, Elisa, additional, Marcheselli, Luigi, additional, Luminari, Stefano, additional, and Merli, Francesco, additional

Published
2021
Full Text
View/download PDF

37. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi

Author

Arcari, Annalisa, primary, Morello, Lucia, additional, Vallisa, Daniele, additional, Marcheselli, Luigi, additional, Tecchio, Cristina, additional, Quaglia, Francesca Maria, additional, Tisi, Maria Chiara, additional, Zilioli, Vittorio Ruggero, additional, Di Rocco, Alice, additional, Perrone, Tommasina, additional, Gini, Guido, additional, Dogliotti, Irene, additional, Bianchetti, Nicola, additional, Bozzoli, Valentina, additional, De Philippis, Chiara, additional, Alvarez De Celis, Maria Isabel, additional, Chiappella, Annalisa, additional, Fabbri, Alberto, additional, Pelosini, Matteo, additional, Merli, Michele, additional, Molinari, Anna Lia, additional, Sciarra, Roberta, additional, Volpetti, Stefano, additional, Hohaus, Stefan, additional, Nassi, Luca, additional, and Visco, Carlo, additional

Published
2021
Full Text
View/download PDF

39. Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience

Author

Zilioli, Vittorio Ruggero, primary, Albano, Domenico, additional, Arcari, Annalisa, additional, Merli, Francesco, additional, Coppola, Alessandra, additional, Besutti, Giulia, additional, Marcheselli, Luigi, additional, Gramegna, Doriana, additional, Muzi, Cristina, additional, Manicone, Moana, additional, Camalori, Manuela, additional, Ciammella, Patrizia, additional, Colloca, Giuseppe, additional, and Tucci, Alessandra, additional

Published
2021
Full Text
View/download PDF

40. 36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Author

Mauro, Francesca Romana, Della Starza, Irene, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Gaidano, Gianluca, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Stelitano, Caterina, Mannina, Donato, Ilariucci, Fiorella, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Belsito Patrizi, Valeria, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pepe, Sara, Andriola, Costanza, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, and Foà, Robin

Published
2023
Full Text
View/download PDF

41. Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Author

Frascione, Pio Manlio Mirko, Novo, Mattia, Castellino, Alessia, Marcheselli, Luigi, Dattoli, Samantha Deianira, Tucci, Alessandra, Gini, Guido, Tarantini, Giuseppe, Mannina, Donato, Arcari, Annalisa, Martiniani, Roberta, Scarpa, Elisabetta, Marino, Dario, Spina, Michele, Gorgone, Ausilia Giuseppa, Di Renzo, Nicola, Mancuso, Salvatrice, Petrucci, Luigi, Tafuri, Agostino, and Vitolo, Umberto

Published
2023
Full Text
View/download PDF

42. Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Author

Boccomini, Carola, Botto, Barbara, Evangelista, Andrea, Zilioli, Vittorio Ruggero, Anastasia, Antonella, Cavallo, Federica, Merli, Francesco, Zanni, Manuela, Tani, Monica, Chiarenza, Annalisa, Liberati, Anna Marina, Conconi, Annarita, Corradini, Paolo, Bari, Alessia, Annechini, Giorgia, Gaidano, Gianluca, Spina, Michele, Sartori, Roberto, Castellino, Claudia, Puccini, Benedetta, Arcari, Annalisa, Bigliardi, Sara, Matta, Giorgia, Merli, Michele, Mannina, Donato, Marino, Dario, Galieni, Piero, Ciambelli, Fabrizio, Musuraca, Gerardo, Bottelli, Chiara, Muzi, Cristina, Ferrero, Simone, Luminari, Stefano, Ladetto, Marco, Ciccone, Giovannino, and Vitolo, Umberto

Published
2023
Full Text
View/download PDF

43. Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Author

Visco, Carlo, Tabanelli, Valentina, Sacchi, Maria Vittoria, Evangelista, Andrea, Ferrarini, Isacco, Tisi, Maria Chiara, Merli, Anna, Fiori, Stefano, Zilioli, Vittorio Ruggero, Re, Alessandro, Castellino, Claudia, Piazza, Francesco, Corradini, Paolo, Hohaus, Stefan, Musuraca, Gerardo, Rossi, Francesca Gaia, Puccini, Benedetta, Cavallo, Federica, Ballerini, Filippo, Sciarra, Roberta, Di Rocco, Alice, Arcari, Annalisa, Boccomini, Carola, Merli, Francesco, Gini, Guido, Tani, Monica, Bruna, Riccardo, Pavone, Vincenzo, Ferreri, Andrés José María, Santoro, Armando, Patti, Caterina, Loseto, Giacomo, Ladetto, Marco, Merli, Michele, Spina, Michele, Zinzani, Pier Luigi, Stefani, Piero Maria, Usai, Sara, Pileri, Stefano, and Balzarotti, Monica

Published
2023
Full Text
View/download PDF

44. Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘

Author

Mauro, Francesca Romana, Reda, Gianluigi, Arena, Valentina, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Laurenti, Luca, Gaidano, Gianluca, Marasca, Roberto, Orsucci, Lorella, Murru, Roberta, Stelitano, Caterina, Ilariucci, Fiorella, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Califano, Catello, Gottardi, Daniela, Liberati, Anna Marina, Pietrasanta, Daniela, Molica, Stefano, Cassin, Ramona, Visentin, Andrea, Vitale, Candida, Lapietra, Gianfranco, Della Starza, Irene, De Propris, Maria Stefania, Raponi, Sara, Nanni, Mauro, Del Giudice, Ilaria, Giuliani, Giorgia, Vignetti, Marco, Guarini, Anna, Albano, Francesco, Neri, Antonino, Cuneo, Antonio, and Foà, Robin

Published
2020
Full Text
View/download PDF

45. Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi

Author

Merli, Francesco, primary, Luminari, Stefano, additional, Tucci, Alessandra, additional, Arcari, Annalisa, additional, Rigacci, Luigi, additional, Hawkes, Eliza, additional, Chiattone, Carlos S., additional, Cavallo, Federica, additional, Cabras, Giuseppina, additional, Alvarez, Isabel, additional, Fabbri, Alberto, additional, Re, Alessandro, additional, Puccini, Benedetta, additional, Barraclough, Allison, additional, Delamain, Marcia Torresan, additional, Ferrero, Simone, additional, Usai, Sara Veronica, additional, Ferrari, Angela, additional, Cencini, Emanuele, additional, Pennese, Elsa, additional, Zilioli, Vittorio Ruggero, additional, Marino, Dario, additional, Balzarotti, Monica, additional, Cox, Maria Christina, additional, Zanni, Manuela, additional, Di Rocco, Alice, additional, Lleshi, Arben, additional, Botto, Barbara, additional, Hohaus, Stefan, additional, Merli, Michele, additional, Sartori, Roberto, additional, Gini, Guido, additional, Nassi, Luca, additional, Musuraca, Gerardo, additional, Tani, Monica, additional, Bottelli, Chiara, additional, Kovalchuk, Sofia, additional, Re, Francesca, additional, Flenghi, Leonardo, additional, Molinari, Annalia, additional, Tarantini, Giuseppe, additional, Chimienti, Emanuela, additional, Marcheselli, Luigi, additional, Mammi, Caterina, additional, and Spina, Michele, additional

Published
2021
Full Text
View/download PDF

47. Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation

Author

Ferreri, Andrés J. M., primary, Sassone, Marianna, additional, Angelillo, Piera, additional, Zaja, Francesco, additional, Re, Alessandro, additional, Di Rocco, Alice, additional, Spina, Michele, additional, Fabbri, Alberto, additional, Stelitano, Caterina, additional, Frezzato, Maurizio, additional, Volpetti, Stefano, additional, Zambello, Renato, additional, Rusconi, Chiara, additional, De Lorenzo, Daniela, additional, Scarano, Eloise, additional, Arcari, Annalisa, additional, Bertoldero, Giovanni, additional, Nonis, Alessandro, additional, Calimeri, Teresa, additional, Perrone, Salvatore, additional, Cecchetti, Caterina, additional, Tarantino, Vittoria, additional, Steffanoni, Sara, additional, Foppoli, Marco, additional, Ciceri, Fabio, additional, and Ponzoni, Maurilio, additional

Published
2020
Full Text
View/download PDF

48. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Author

Merli, Michele, primary, Defrancesco, Irene, additional, Visco, Carlo, additional, Besson, Caroline, additional, Di Rocco, Alice, additional, Arcari, Annalisa, additional, Sica, Antonello, additional, Cencini, Emanuele, additional, Tisi, Maria Chiara, additional, Frigeni, Marco, additional, Grossi, Paolo, additional, Bianchi, Benedetta, additional, Mora, Barbara, additional, Bertù, Lorenza, additional, Bruno, Raffaele, additional, Passamonti, Francesco, additional, and Arcaini, Luca, additional

Published
2020
Full Text
View/download PDF

49. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience.

Author

Massaro, Fulvio, Pavone, Vincenzo, Stefani, Piero Maria, Botto, Barbara, Pulsoni, Alessandro, Patti, Caterina, Cantonetti, Maria, Visentin, Andrea, Scalzulli, Potito Rosario, Rossi, Andrea, Galimberti, Sara, Cimminiello, Michele, Gini, Guido, Musso, Maurizio, Sorio, Marco, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Luppi, Mario, Mannina, Donato, and Fabbri, Alberto

Subjects
STEM cell transplantation, HODGKIN'S disease, DISEASE relapse, PROGRESSION-free survival, SALVAGE therapy
Abstract

The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression‐free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post‐ASCT BV maintenance in the real‐life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow‐up was 20 months. Patients presented a median of two lines of treatment pre‐ASCT, with 51% receiving BV. Twenty‐nine percent of patients had at least two high‐risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET‐CT, a Deauville score (DS) of 1–3 was reported in 75% and 78% of pre‐ and post‐ASCT evaluations, respectively. Grade 3–4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three‐year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3‐year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post‐ASCT DS 4–5 (HR 3.14; p = 0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post‐ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results